Fundraising Fox
/Companies
Sign in

FEMSelect

Founded 2012 · 14 employees on LinkedIn · 8 known investors

Find your way into FEMSelect

Each arrow is one introduction. Sign up to fill in the first one.

138 people can intro you to Sasha

Ask Dani Goldsher to introduce you to Sasha Schrode

You →Dani · together at FEMSelect →Sasha

Sign up to find every way you can get introduced to FEMSelect

  • Your email: who you already know at FEMSelect, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the FEMSelect team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

FemSelect develops EnPlace, an FDA-cleared, minimally invasive same-day treatment for Pelvic Organ Prolapse in women. The device addresses dropping of the uterus and cervix by supporting the pelvic floor, offering an alternative to pessaries, physical therapy, and Kegels.

Digital HealthFemTechMedical Devices

Founders & leadership

SS
Sasha SchrodeChief Executive OfficerSasha Schrode is CEO of FEMSelect, a women's health company developing minimally invasive treatments for pelvic organ prolapse. She previously founded and led Serpex Medical, a lung cancer MedTech company, until its acquisition by Maverix Medical in 2023, and held commercial leadership roles at Schering-Plough and C.R. Bard; she holds an MBA from Northeastern University and a BA from Purdue's business school.

Investors · 8

TransPacific Venture Partnerslisted by TransPacific Venture PartnersTaipei City · $500K – $3M

How we know: TransPacific Venture Partners's portfolio page · Not right? Tell us

Triventureslisted by TriventuresHerzliya · $1M – $3M

How we know: funding news · futurefemhealth.com · the VCSheet dataset · Not right? Tell us

New Age VenturesreportedNew York

How we know: funding news · futurefemhealth.com · Not right? Tell us

Also in the syndicate · 4

Avea VenturesNordwand CapitalRAD BiomedTerra Verde Comp

Funding

SEC filings, press & company announcements

$9M disclosed across 1 of 4 rounds · 2022–2026

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 1

Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.

Companies working in the same space as FEMSelect.

In the news

FEMSelect Announces Close of Oversubscribed Series B Equity Financing to Drive Commercial Growth, Leadership Transformation, and Global Expansion - FEMSelectfemselect.com · Feb 2026

Frequently asked questions

What does FEMSelect do?
FemSelect develops EnPlace, an FDA-cleared, minimally invasive same-day treatment for Pelvic Organ Prolapse in women. The device addresses dropping of the uterus and cervix by supporting the pelvic floor, offering an alternative to pessaries, physical therapy, and Kegels.
Who are FEMSelect's investors?
FEMSelect's investors include Robin Hood Ventures, TransPacific Venture Partners, Triventures, New Age Ventures.
How much funding has FEMSelect raised?
FEMSelect has disclosed $9M raised across 1 of its 4 known rounds.